预约演示
更新于：2026-02-25
Piroxicam
吡罗昔康
更新于：2026-02-25
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1982-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13N3O4S |
InChIKeyQYSPLQLAKJAUJT-UHFFFAOYSA-N |
CAS号36322-90-4 |
关联
60
项与 吡罗昔康 相关的临床试验NCT07281807
Comparison of the Pain Levels of Single-Dose Premedication With Piroxicam and Prednisolone on Post-Endodontic Pain in Single-Visit Root Canal Treatment of Premolars
IRCT20250622066221N1
A comparative study of the efficacy of piroxicam ampoule mesotherapy injection and shockwave modality on the clinical manifestations of knee osteoarthritis patients
NCT06727734
Levonorgestrel-piroxicam Combination Versus Ulipristal Acetate for Emergency Contraception: a Randomised Double-blind Controlled Trial
100 项与 吡罗昔康 相关的临床结果
登录后查看更多信息
100 项与 吡罗昔康 相关的转化医学
登录后查看更多信息
100 项与 吡罗昔康 相关的专利（医药）
登录后查看更多信息
4,834
项与 吡罗昔康 相关的文献（医药）2026-02-01JOURNAL OF ETHNOPHARMACOLOGY
In vivo and in silico assays demonstrate that the hydroalcoholic extract of Aloysia polystachya and carvone promote anti-ulcer effects
Article
作者: Maccagnan, Juliana C ; Freschi, Khetlyn ; Steffler, Amanda M ; Borba, Ana L T ; Gutiérrez, Max Vidal ; Somensi, Lincon B ; da Silva, Luisa Mota ; Dalla Cort, Tainara V T ; Miorando, Daniela ; Ferraz, Cleidiane V ; Von Dentz, André L ; Marcelino, Adan P N ; Roman, Maria I ; Oss, Camile F ; Dalla Vecchia, Cristian A ; Roman Junior, Walter Antônio
ETHNOPHARMACOLOGICAL IMPORTANCE:
Aloysia polystachya (Griseb.) Moldenke is a medicinal plant that has long been used in South American medicine to treat a variety of diseases, most notably gastrointestinal issues. Despite its well-known ethnobotanical usage, this plant's putative anti-gastric ulcer action has yet to be investigated.
AIM OF THE STUDY:
To evaluate the gastroprotective and gastric healing effects of the hydroalcoholic extract from Aloysia polystachya (HEAp) and its bioactive compound, carvone, through both in vivo and in silico approaches. Additionally, it seeks to elucidate the pharmacological mechanisms underlying these biological effects.
MATERIALS AND METHODS:
First, phytochemical tests were performed with HEAp. Next, to demonstrate the gastroprotective activities, rats were orally treated with HEAp (30, 100, or 300 mg/kg) or carvone (3 mg/kg) before induction with ulcerative agents (ethanol or piroxicam). Furthermore, the role of prostaglandins, α-2 adrenergic receptors, nitric oxide, and sulfhydryl compounds were investigated. Additionally, the antisecretory activity of HEAp was investigated using a pylorus ligation model. For gastric healing analysis, acetic acid-induced chronic ulcer was used, in which rats were treated with HEAp at 100 mg/kg. Biochemical evaluations included measurements of myeloperoxidase (MPO), superoxide dismutase (SOD), glutathione S-transferase (GST), glutathione reduced (GSH) levels, and lipid peroxides (LPO) in ulcerated tissues. Finally, computational studies, including network pharmacology and molecular docking analyses, were conducted to explore the potential pharmacological targets of HEAp phytoconstituents.
RESULTS:
Mass spectrometry analysis (ESI-MS) identified four compounds: caffeic, p-coumaric, gallic acids, and epigallocatechin, which, along with carvone, were used in the in-silico analyses. Oral administration of HEAp (100 or 300 mg/kg) and carvone (3 mg/kg) significantly prevented ethanol- and piroxicam-induced gastric ulcers, as corroborated by histopathological assessments. Furthermore, pretreatment with N-ethylmaleimide (NEM) abolished the gastroprotective effects of both agents, implicating the involvement of sulfhydryl compounds in their modes of action. In the pylorus ligation assay, carvone (3 mg/kg) notably increased gastric pH and reduced acidity and peptic activity, mirroring the effects of omeprazole. Additionally, HEAp (100 mg/kg) and carvone (3 mg/kg) accelerated acetic acid-induced gastric ulcer healing by 75.06 % and 76.18 %, respectively, as supported by histological and histochemical analyses. Moreover, the healing effects of HEAp and carvone diminished MPO activity and LPO, along with elevated GSH levels and enhanced GST and SOD activities. In silico, carvone presented a binding mode similar to the co-crystallized substrate vonoprazan and effective interactions with the protein MPO, which highlights the compound's potential as a natural therapeutic agent for the treatment of gastric ulcers.
CONCLUSION:
The findings of this study demonstrate that the hydroalcoholic extract of A. polystachya (HEAp) and its bioactive compound carvone possess significant gastroprotective and gastric healing properties. These effects are likely mediated through the modulation of sulfhydryl compounds, anti-inflammatory and antioxidant defenses, and antisecretory mechanisms. The identification of phenolic constituents, combined with in silico analyses, further supports the potential therapeutic relevance of HEAp and carvone. Collectively, these results highlight that the phytoconstituents from A. polystachya corroborate the traditional use of the plant and are promising candidates for the investigation of anti-ulcer gastric agents.
2026-01-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis
Review
作者: Tawfik, Abdelrahman G. ; Trinkley, Katy E. ; Reese, Thomas ; Del Fiol, Guilherme ; Jones, Aubrey ; Malone, Daniel C. ; Kawamoto, Kensaku ; Gomez‐Lumbreras, Ainhoa
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety. This systematic review and meta‐analysis aimed to quantify the risk of GI bleeding associated with individual NSAIDs. We searched PubMed from inception through January 2025 using MeSH and free‐text terms for “gastrointestinal bleeding” and nine commonly used NSAIDs. A random effects meta‐analysis was conducted to estimate the pooled odds ratios (ORs) for GI bleeding, with hazard ratios (HRs) and relative risks (RRs) treated as approximations of ORs due to the rare event nature of GI bleeding. Of 6,711 records screened, 25 studies met the inclusion criteria. Substantial heterogeneity in study design, populations, and outcome ascertainment was observed. Celecoxib was associated with the lowest risk of GI bleeding (OR 1.16, 95% CI: 0.84–1.61). Among non‐selective NSAIDs, ibuprofen had the lowest significant risk (OR 2.28, 95% CI: 1.71–3.03), while ketorolac showed the highest risk (OR 20.67, 95% CI: 14.56–29.34). Other agents, such as piroxicam and meloxicam, also demonstrated significantly elevated risks. The risk of GI bleeding varies widely among individual NSAIDs. Celecoxib appears to have the lowest GI risk, though cardiovascular safety must also be considered. These findings highlight the need for personalized NSAID selection and suggest that NSAIDs should not be treated as a uniform class when assessing bleeding risk.
2025-12-01BIOMEDICINE & PHARMACOTHERAPY
Curcumin impacts on cisplatin sensitivity determining apoptotic boost in mesothelioma
Article
作者: Cuciniello, Rossana ; Filosa, Stefania ; Rinaldi, Elena ; Baldi, Alfonso ; Meo, Francesco Di ; Crispi, Stefania ; Petillo, Gianluigi ; Piccioni, Miriam ; Valentino, Anna ; Petillo, Orsolina ; Bergamo, Paolo ; Caputo, Emilia
Cancer is one of the main diseases causing one-third of the worldwide death every year. The recent progresses achieved in chemotherapy have increased patients' survival, however, drug efficacy is limited by the occurrence of serious side effects and the development of drug resistance. To overcome these problems, research interests, aim to develop alternative therapies based on the use of polyphenols, such as curcumin. Polyphenols are effective against different cancers and in combination with standard drugs, display synergism enhancing anticancer effects. Malignant mesothelioma (MM) is an aggressive cancer associated with exposure to asbestos fibers for which to date, neither surgical nor chemotherapy, based on the use of cisplatin and other platinum drugs, result in a favorable prognosis. We previously reported that daily administration of a curcumin standardized extract exerted anticancer effects in MM in vitro and in vivo. The efficacy of this formulation has been tested in several clinical trials in combination to standard drugs. Since curcumin is known to increase cisplatin sensitivity in different cancer, here we evaluated the ability of this formulation in enhancing cisplatin sensitivity in MM. The effect of combined treatment was evaluated in 2D and 3D cultures by using two MM cell lines, MSTO-211H and Ist-Mes2, that are sensitive or less responsive to the piroxicam/cisplatin combined treatment respectively. Results indicate that this treatment determines a dramatic apoptotic increase linked to a concomitant inactivation of Nrf2, a transcription factor with a key role in carcinogenesis, and of NUPR1, a transcriptional regulator involved in drug chemoresistance.
100 项与 吡罗昔康 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2007-02-28 | |
| 肌痛 | 日本 | 1986-09-25 | |
| 肩关节周围炎 | 日本 | 1986-09-25 | |
| 网球肘 | 日本 | 1986-09-25 | |
| 腱鞘炎 | 日本 | 1986-09-25 | |
| 创伤和损伤 | 日本 | 1986-09-25 | |
| 骨关节炎 | 美国 | 1982-04-06 | |
| 类风湿关节炎 | 美国 | 1982-04-06 | |
| 疼痛 | 中国 | 1982-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | - | 1,383 | 蓋觸繭窪觸網願鹹簾壓(艱網壓壓簾選願選網觸) = 壓憲廠衊鹹製窪窪醖網 糧艱憲鹹膚艱鑰淵遞餘 (醖淵鹹簾鬱願獵襯壓鹽 ) 更多 | 不佳 | 2024-08-01 | ||
蓋觸繭窪觸網願鹹簾壓(艱網壓壓簾選願選網觸) = 醖鬱鹽範獵淵鹹範淵廠 糧艱憲鹹膚艱鑰淵遞餘 (醖淵鹹簾鬱願獵襯壓鹽 ) 更多 | |||||||
临床2/3期 | 860 | (Piroxicam) | 網夢艱製壓醖願築觸醖 = 齋簾選鏇簾願簾選鹽糧 鬱醖鬱夢壓膚網願襯顧 (鬱窪廠積構鑰繭夢夢餘, 網積願憲範簾網蓋膚繭 ~ 糧繭鹽齋衊範顧觸構襯) 更多 | - | 2024-05-06 | ||
(Placebo) | 網夢艱製壓醖願築觸醖 = 淵糧積壓簾願構繭襯鬱 鬱醖鬱夢壓膚網願襯顧 (鬱窪廠積構鑰繭夢夢餘, 繭願築構餘顧鏇繭鹹衊 ~ 鑰蓋襯鏇構齋選鑰窪選) 更多 | ||||||
临床4期 | 105 | 構齋鑰鬱願願糧鬱夢選(繭鏇顧顧製淵顧鏇築蓋) = 繭築簾繭醖廠繭製積選 繭網糧選遞醖鑰夢製獵 (築鏇夢蓋餘選襯顧選糧, 25) 更多 | - | 2020-09-16 | |||
临床3期 | 54 | ACTX | 膚襯獵鹹積繭糧憲鹹艱(簾範遞製製構遞選糧製) = 窪鏇膚願網繭窪遞選鏇 衊壓網襯膚簾夢糧簾衊 (糧簾製齋窪願鏇繭鏇範 ) 更多 | - | 2019-10-01 | ||
N/A | - | 70 | 憲糧窪鏇築膚遞顧醖願(構廠築鑰襯窪鏇襯構簾) = 18% 鹽鬱積憲壓繭憲艱襯製 (獵獵醖艱鹹鏇憲構襯鹽 ) 更多 | - | 2001-06-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用